Evidence map›Paper›PMID 29194575›Full record

ArticleClinical and experimental immunology2018

The adjuvant system AS01 up-regulates neutrophil CD14 expression and neutrophil-associated antigen transport in the local lymphatic network.

M R Neeland, W Shi, C Collignon, E N T Meeusen, A M Didierlaurent, M J de Veer

Abstract read
In one paragraph

Article in Clinical and experimental immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

M R NeelandBiotechnology Research Laboratories, School of Biomedical Sciences, Monash University, Clayton, Victoria, Australia.ORCID 0000-0001-7301-9982
W ShiBiotechnology Research Laboratories, School of Biomedical Sciences, Monash University, Clayton, Victoria, Australia.
C CollignonGSK Vaccines, Rixensart, Belgium.
E N T MeeusenBiotechnology Research Laboratories, School of Biomedical Sciences, Monash University, Clayton, Victoria, Australia.
A M DidierlaurentGSK Vaccines, Rixensart, Belgium.
M J de VeerBiotechnology Research Laboratories, School of Biomedical Sciences, Monash University, Clayton, Victoria, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The liposome-based adjuvant system AS01 is under evaluation for use in several vaccines in clinical development. We have shown previously that AS01 injected with hepatitis B surface antigen (HBsAg) induces a distinct cellular signature within the draining lymphatics that enhances local lymphocyte recruitment and antigen-specific humoral immunity. Here, we show that AS01-induced neutrophil recruitment is associated with increased expression of CD14 and enhanced antigen uptake capacity in neutrophils from both afferent and efferent lymphatic compartments during the first 48 h after vaccination. Significant and transient increases in CD14 expression on systemic neutrophils were also observed following primary and boost vaccination with HBsAg-AS01; however, they were not observed following additional encounter with HBsAg-alone or HBsAg-alum. These results show that following immunization with AS01, neutrophils expressing higher levels of CD14 are both more abundant and efficient at antigen uptake, warranting further investigation into the role of neutrophil-associated CD14 in the adjuvanticity of AS01.

Indexed as

Adjuvants, ImmunologicAnimalsBiological TransportCD4-Positive T-LymphocytesDrug CombinationsHepatitis B Surface AntigensImmunity, HumoralLipid ALipopolysaccharide ReceptorsLymphatic SystemMiceNeutrophilsSaponinsTranscriptional ActivationUp-RegulationVaccinationAdjuvants, Immunologicadjuvant system 01Drug CombinationsHepatitis B Surface AntigensLipid ALipopolysaccharide ReceptorsSaponinsantigen presentation/processingcell traffickingneutrophilsvaccination

Identifiers

PMID29194575
PMCPMC5842410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.